DE602004021269D1 - 5-arylpyrimidine als anti-krebs-mittel - Google Patents

5-arylpyrimidine als anti-krebs-mittel

Info

Publication number
DE602004021269D1
DE602004021269D1 DE602004021269T DE602004021269T DE602004021269D1 DE 602004021269 D1 DE602004021269 D1 DE 602004021269D1 DE 602004021269 T DE602004021269 T DE 602004021269T DE 602004021269 T DE602004021269 T DE 602004021269T DE 602004021269 D1 DE602004021269 D1 DE 602004021269D1
Authority
DE
Germany
Prior art keywords
arylpyrimidine
cancer medium
cancer
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004021269T
Other languages
German (de)
English (en)
Inventor
Nan Zhang
Semiramis Ayral-Kaloustian
Thai Hiep Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Wyeth LLC
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC filed Critical Wyeth Holdings LLC
Publication of DE602004021269D1 publication Critical patent/DE602004021269D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602004021269T 2003-09-24 2004-09-17 5-arylpyrimidine als anti-krebs-mittel Expired - Fee Related DE602004021269D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50548703P 2003-09-24 2003-09-24
PCT/US2004/030682 WO2005030216A1 (en) 2003-09-24 2004-09-17 5-arylpyrimidines as anticancer agents

Publications (1)

Publication Number Publication Date
DE602004021269D1 true DE602004021269D1 (de) 2009-07-09

Family

ID=34393022

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004021269T Expired - Fee Related DE602004021269D1 (de) 2003-09-24 2004-09-17 5-arylpyrimidine als anti-krebs-mittel

Country Status (24)

Country Link
US (1) US7524849B2 (enExample)
EP (1) EP1663241B1 (enExample)
JP (1) JP2007506746A (enExample)
KR (1) KR20060089215A (enExample)
CN (1) CN1871009A (enExample)
AR (1) AR045811A1 (enExample)
AT (1) ATE432077T1 (enExample)
AU (1) AU2004275733A1 (enExample)
BR (1) BRPI0414736A (enExample)
CA (1) CA2539235A1 (enExample)
CO (1) CO5690592A2 (enExample)
DE (1) DE602004021269D1 (enExample)
EC (1) ECSP066457A (enExample)
GT (1) GT200400188A (enExample)
IL (1) IL174305A0 (enExample)
MX (1) MXPA06003207A (enExample)
NO (1) NO20061319L (enExample)
PA (1) PA8613201A1 (enExample)
PE (1) PE20050470A1 (enExample)
RU (1) RU2006107578A (enExample)
SA (1) SA04250303A (enExample)
TW (1) TW200512198A (enExample)
WO (1) WO2005030216A1 (enExample)
ZA (1) ZA200602386B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
CN101193884A (zh) 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
WO2006138180A1 (en) * 2005-06-13 2006-12-28 Wyeth Tubulin inhibitor and process for its preparation
US20110201496A1 (en) * 2006-03-27 2011-08-18 Joachim Rheinheimer Substituted 5-Hetaryl-4-Aminopyrimidines
CL2007002231A1 (es) * 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
AR064852A1 (es) * 2007-01-11 2009-04-29 Basf Ag Pirimidinas sustituidas en posicion 2
WO2009007187A1 (de) * 2007-07-09 2009-01-15 Basf Se Substituierte 5-hetarylpyrimidine
EP4328223A3 (en) 2011-04-22 2024-11-06 Signal Pharmaceuticals, LLC Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
WO2014047257A2 (en) * 2012-09-19 2014-03-27 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CN107108524A (zh) 2014-12-16 2017-08-29 西格诺药品有限公司 2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ,エルエルシー 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2017019487A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
WO2019169111A1 (en) 2018-03-02 2019-09-06 The Trustees Of The University Of Pennsylvania [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules
JP7109684B2 (ja) * 2019-11-01 2022-07-29 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US88096A (en) * 1869-03-23 t h a y e r
US116429A (en) * 1871-06-27 Improvement in dial-telegraph apparatus
US69242A (en) * 1867-09-24 Calvin pepper
US147744A (en) * 1874-02-24 Improvement in locomotive-furnaces
US61889A (en) * 1867-02-05 Improvement in animal teaps
GB9700664D0 (en) 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
US6117876A (en) 1997-04-14 2000-09-12 American Cyanamid Company Fungicidal trifluorophenyl-triazolopyrimidines
DE69934224T2 (de) 1998-04-27 2007-10-04 Kumiai Chemical Industry Co., Ltd. 3-arylphenylsulfid-derivate und insektizide und mitizide
US5986135A (en) 1998-09-25 1999-11-16 American Cyanamid Company Fungicidal trifluoromethylalkylamino-triazolopyrimidines
US6156925A (en) 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
EA005927B1 (ru) 2000-06-13 2005-08-25 Басф Акциенгезельшафт Фунгицидные 5-фенил-замещенные 2-(цианоамино)пиримидины
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
CZ20032475A3 (cs) 2001-03-15 2003-12-17 Basf Aktiengesellschaft 5-Fenylpyrimidiny, způsob jejich přípravy, meziprodukty pro jejich přípravu a jejich použití pro kontrolu škodlivých hub
ATE297390T1 (de) 2001-04-20 2005-06-15 Ciba Sc Holding Ag 4-amino-2-(2-pyridinyl)pyrimidine als mikrobizide wirksubstanzen
MXPA04004583A (es) 2001-11-19 2004-08-13 Basf Ag 5-fenilpirimidinas, agentes que comprenden las mismas, metodo de produccion y uso de la misma.
WO2003070721A1 (de) 2002-02-21 2003-08-28 Basf Aktiengesellschaft 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
DE60314730T2 (de) 2002-03-15 2008-06-05 Ciba Specialty Chemicals Holding Inc. Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.

Also Published As

Publication number Publication date
US7524849B2 (en) 2009-04-28
EP1663241A1 (en) 2006-06-07
EP1663241B1 (en) 2009-05-27
NO20061319L (no) 2006-04-20
PE20050470A1 (es) 2005-10-03
ECSP066457A (es) 2006-09-18
WO2005030216A1 (en) 2005-04-07
ATE432077T1 (de) 2009-06-15
PA8613201A1 (es) 2005-11-25
US20050075357A1 (en) 2005-04-07
SA04250303A (ar) 2005-12-03
IL174305A0 (en) 2008-02-09
TW200512198A (en) 2005-04-01
RU2006107578A (ru) 2007-10-27
MXPA06003207A (es) 2006-06-23
GT200400188A (es) 2005-05-02
JP2007506746A (ja) 2007-03-22
ZA200602386B (en) 2009-03-25
CA2539235A1 (en) 2005-04-07
KR20060089215A (ko) 2006-08-08
AR045811A1 (es) 2005-11-16
CO5690592A2 (es) 2006-10-31
AU2004275733A1 (en) 2005-04-07
BRPI0414736A (pt) 2006-11-21
CN1871009A (zh) 2006-11-29

Similar Documents

Publication Publication Date Title
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
EP1744688A4 (en) MIDDLE DISTRACTOR
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
SE0302991L (sv) Spånskiva
DE602004015711D1 (de) Tintenstrahldrucker
DE602004006448D1 (de) Tintenstrahldrucker
ATE363383T1 (de) Schlingenware
DE602004002346D1 (de) Tintenstrahldrucker
DE602004026391D1 (de) Tintenstrahldrucker
DE602004006034D1 (de) Tintenstrahldrucker
DE602004001949D1 (de) Tintenstrahldrucker
DE602004020408D1 (de) Tintenstrahldrucker
AT502792A5 (de) Düsenanpressvorrichtung
DE602004021269D1 (de) 5-arylpyrimidine als anti-krebs-mittel
DE602004020037D1 (de) Tintenstrahldrucker
DE602004000414D1 (de) Tintenstrahldrucker
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
DE602004023980D1 (de) Tintenstrahldrucker
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
DE602004000639D1 (de) Tintenstrahldrucker
DE602004019236D1 (de) Tintenstrahldrucker
DE602005015844D1 (de) Kompaktes stellglied
FR2851312B1 (fr) Support antivibratoire hydraulique

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee